Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

FDA considerations regarding new hypolipidemic agents

M J Finkel

    Lipids
    |January 1, 1977
    PubMed
    Summary
    This summary is machine-generated.

    New Food and Drug Administration (FDA) policies require hypolipidemic agents to prove long-term safety through postmarketing studies and demonstrate clinical effectiveness. Effectiveness will be measured by reductions in xanthomata, atherosclerotic plaque, and related cardiovascular or cerebrovascular events, including mortality.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    White-blood-cell monitoring and clozapine.

    Lancet (London, England)·1995
    Same author

    Normal volunteers should not be used for bioavailability or bioequivalence studies of clozapine.

    Pharmaceutical research·1994
    Same author

    Nervous system Lyme borreliosis--revisited [corrected; erratum to be published].

    Archives of neurology·1992
    Same author

    The relationships of the American Society for Clinical Pharmacology and Therapeutics to government.

    Clinical pharmacology and therapeutics·1990
    Same author

    Orphan products development and some methods for maximizing the usefulness of research on rare diseases.

    Progress in clinical and biological research·1985
    Same author

    Adoption of orphan products by the pharmaceutical industry.

    The New England journal of medicine·1984

    Area of Science:

    • Pharmacology and Therapeutics
    • Regulatory Science
    • Cardiovascular Medicine

    Background:

    • The development of novel hypolipidemic agents necessitates rigorous evaluation.
    • Existing regulatory frameworks guide the approval process for cardiovascular drugs.
    • Ensuring patient safety and therapeutic benefit is paramount for new medications.

    Purpose of the Study:

    • To outline the proposed Food and Drug Administration (FDA) policy for new hypolipidemic agents.
    • To define the required evidence for demonstrating long-term safety and clinical effectiveness.
    • To specify the clinical endpoints for judging the efficacy of these drugs.

    Main Methods:

    • Postmarketing studies are mandated for long-term safety assessment.
    • Clinical effectiveness must be demonstrated within a defined timeframe.

    Related Experiment Videos

  • Randomized double-blind trials are considered the necessary standard for evidence generation.

    • Main Results:

    • Effectiveness endpoints include reduction of xanthomata and atherosclerotic plaque.
    • Morbidity reduction in coronary artery disease and peripheral/cerebral atherosclerosis is a key measure.
    • Mortality reduction is also a critical criterion for effectiveness.

    Conclusions:

    • The proposed FDA policy emphasizes comprehensive safety and efficacy evaluation.
    • Robust clinical trial data, particularly randomized double-blind trials, are essential.
    • These stringent requirements aim to ensure the benefit-risk profile of new hypolipidemic drugs.